In an attempt to characterize antibody responses to the HERV-K (HML-2) Env protein it was found that antibody levels to the epitope HERV-K (HML-2) Env-SU 19–37 significantly correlated with clinical measures of disease severity in individuals with ALS [62]. This evidence concerns the gene CLEC10A and amyotrophic lateral sclerosis.